We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

BN:EURONEXT PARISDanone SA Analysis

Data as of 2026-06-22 - not real-time

$44.44

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Brookfield Corporation (BN) is trading at $44.44, which sits below its 20‑day, 50‑day and 200‑day SMAs (45.20, 45.31 and 45.04 respectively) and is accompanied by a neutral RSI of 45.8 and a bearish MACD crossover, suggesting short‑term price pressure. Support sits at $43.57 with resistance near $46.70, leaving the stock modestly above the nearest floor but still vulnerable to a downside move. The current trailing PE of 87.1 is dramatically higher than the industry average of 16.9, flagging the stock as overvalued on a historical earnings basis, yet the forward PE of 7.6 signals a sharp earnings rebound expected from the recent acquisition push highlighted in the credit‑concern news. Dividend yield is low at 0.63% with a payout ratio of 49%, and free cash flow is negative, raising modest sustainability questions despite positive operating cash flow. The balance sheet is leveraged, with a debt‑to‑equity ratio of 161, and the beta of ~1.55 (1.84 on the quote) combined with a 30% 30‑day volatility underscores heightened market risk. Analyst consensus remains bullish (Buy) with a median price target of $56, implying roughly 22% upside, and market sentiment is in “Extreme Greed” mode (Fear‑Greed Index 90.8).
In the medium to long term, Brookfield’s diversified asset base across real estate, infrastructure and renewable power, coupled with its opportunistic buying in a stressed credit environment, could drive significant earnings growth, justifying the attractive forward valuation. However, the high leverage, modest dividend yield, and current technical weakness temper enthusiasm, suggesting a cautious approach that balances the upside potential against the elevated risk profile.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price below key moving averages and bearish MACD
  • High current PE relative to peers
  • Support level provides limited downside cushion

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Forward PE of 7.6 indicating strong earnings upside
  • Analyst price targets imply ~22% upside
  • Strategic asset acquisitions amid credit market stress

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Diversified global asset portfolio supporting stable cash flows
  • Elevated leverage (Debt/Equity > 160) poses balance‑sheet risk
  • Modest dividend yield with payout near 50% of earnings

Key Metrics & Analysis

Financial Health

Revenue Growth7.90%
Profit Margin1.69%
P/E Ratio87.1
ROE2.50%
ROA2.64%
Debt/Equity161.47
P/B Ratio2.3
Op. Cash Flow$9.5B
Free Cash Flow$-2218749952
Industry P/E16.9

Technical Analysis

TrendNeutral
RSI45.8
Support$43.57
Resistance$46.70
MA 20$45.20
MA 50$45.31
MA 200$45.04
MACDBearish
VolumeStable
Fear & Greed Index90.77

Valuation

Target Price$54.40
Upside/Downside22.41%
GradeOvervalued
TypeGrowth
Dividend Yield0.63%

Risk Assessment

Beta1.55
Volatility30.83%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.